UNICREDIT BANK/CALL/ROCHE GS/260/0.1/18.06.25 Share Price

Warrant

DE000HD4W807

Real-time BOERSE MUENCHEN 16:45:52 05/07/2024 BST
1.14 EUR +3.64% Intraday chart for UNICREDIT BANK/CALL/ROCHE GS/260/0.1/18.06.25
Current month-23.61%
1 month+19.57%
Date Price Change
05/07/24 1.14 +3.64%
04/07/24 1.1 -9.09%
03/07/24 1.21 -9.70%
02/07/24 1.34 -2.19%
01/07/24 1.37 -4.86%

Real-time BOERSE MUENCHEN

Last update July 05, 2024 at 04:45 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer UniCredit UniCredit
WKN HD4W80
ISINDE000HD4W807
Date issued 22/04/2024
Strike 260 CHF
Maturity 18/06/2025 (348 Days)
Parity 10 : 1
Emission price 0.74
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.72
Lowest since issue 0.48
Spread 0.04
Spread %3.51%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
243.4 CHF
Average target price
276.4 CHF
Spread / Average Target
+13.57%
Consensus